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Rapid, simple and inexpensive measures are needed to assess the efficacy of reperfusion
therapy both in clinical practice and in clinical trials testing novel reperfusion regimens. In the
last decade, several observations have led to a favorable reappraisal of the utility of ST segment
monitoring as a simple means of assessing reperfusion in patients receiving fibrinolytic
therapy for acute ST elevation myocardial infarction, and ST resolution is being used
increasingly in clinical practice and in clinical research. This review focuses on four
interrelated roles for ST segment monitoring: the assessment of epicardial reperfusion and the
identification of candidates for rescue percutaneous coronary intervention; the evaluation of
microvascular and tissue-level reperfusion; the determination of prognosis early after
fibrinolytic therapy; and the use of ST segment resolution to compare different reperfusion
regimens. (J Am Coll Cardiol 2001;38:1283–94) © 2001 by the American College of
Cardiology
In 1969 one of the present authors and his collaborators
demonstrated that myocardial ischemic injury after coronary
artery occlusion is not fixed but can be influenced pro-
foundly by altering the balance between myocardial oxygen
supply and demand (1). In dogs with occluded coronary
arteries, the magnitude of ST segment elevation correlated
well with subsequent depression of myocardial creatine
kinase activity (2) and with evidence of myocardial necrosis
on histologic examination (2,3). The height of the ST
segment on epicardial electrocardiograms (ECG) was,
therefore, utilized as an index of the severity of ischemic
injury. In considering how this approach could be utilized
clinically, extension from the epicardial to the surface ECG
was considered, and a close correspondence between the
precordial and epicardial ECG was described (3,4) (Fig. 1).
In the dog with coronary occlusion, myocardial reperfu-
sion was accompanied by rapid normalization of ST seg-
ment elevation (5). A decade later, with the clinical devel-
opment of thrombolytic therapy for acute myocardial
infarction (MI), similar observations were made in humans
(6). ST segment resolution was subsequently evaluated in a
number of studies to determine its accuracy for predicting
patency of the infarct-related artery (IRA) (7–11), but no
clear consensus was reached on the utility of this measure-
ment. Thus, coronary angiography has remained the “gold
standard” for identifying promising reperfusion regimens
that merit evaluation in large phase III trials.
In the last decade, several observations have led to a
reappraisal of the utility of ST segment monitoring after ST
elevation MI (STEMI). First, Schro¨der and colleagues
(12,13) showed that ST segment resolution can predict
accurately the risk for death and congestive heart failure
(CHF) in patients treated with fibrinolytic therapy (12,13).
Subsequent studies confirmed a remarkably consistent rela-
tionship between the degree of ST resolution and subse-
quent mortality (Fig. 2). Second, Ito et al. (14,15) demon-
strated that restoration of normal epicardial blood flow is
not sufficient to ensure adequate myocardial reperfusion; the
latter requires perfusion at the level of the coronary micro-
circulation and myocytes. Novel reperfusion regimens have
been developed that incorporate both fibrinolytic and anti-
platelet therapies (16–18), and these therapies may be
particularly effective in the coronary microcirculation
(19,20).
Resolution of ST segment elevation is now being used
with increasing frequency in clinical trials and patient
management. This review will focus on four interrelated
roles for ST segment monitoring:
1. Assessment of epicardial reperfusion and identification
of candidates for rescue percutaneous coronary interven-
tion (PCI);
2. Evaluation of microvascular and tissue-level reperfusion;
3. Determination of prognosis early after fibrinolytic ther-
apy; and
4. Direct comparison of different reperfusion regimens.
IDENTIFICATION OF CANDIDATES FOR RESCUE PCI
Patients who fail to achieve normal Thrombolysis In Myo-
cardial Infarction (TIMI) grade 3 epicardial blood flow after
fibrinolytic therapy are at high risk for the development of
death and CHF (21,22). Data to support urgent “rescue”
PCI in patients with an occluded infarct artery are limited to
retrospective studies (23,24) and several small randomized
clinical trials (25). Unfortunately, it has become extremely
difficult to study directly the efficacy of rescue PCI because,
after identifying an occluded IRA by angiography, most
investigators are not willing to randomize patients to a
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strategy that does not involve PCI (26). Although the
studies to date have major limitations, the weight of
evidence supports the value of rescue PCI in moderate- to
high-risk patients with an occluded IRA after fibrinolytic
therapy (26). Furthermore, it is likely that the relative
benefits of rescue PCI have increased in the modern
interventional era due to the introduction of glycoprotein
IIb/IIIa (GP IIb/IIIa) inhibitors (27), stenting (28) and
improved vascular access site management. These advances
should decrease the probability of failed rescue PCI, which
is associated with mortality rates as high as 30% to 50%
(23,24,29–31).
The role of rescue PCI for patients with TIMI grade 2
flow is less well established, because residual stenosis and
thrombosis may play only a contributory role in the patho-
genesis of TIMI grade 2 flow. Many patients with TIMI
grade 2 flow after reperfusion therapy have sluggish flow on
the basis of increased microvascular resistance rather than a
flow-limiting epicardial stenosis (32). Two small random-
ized trials of rescue PCI have been performed among
patients with TIMI grade 2 flow (26,33), and neither has
demonstrated an improvement in clinical outcomes. Thus,
larger, prospective trials are needed to address this impor-
tant question.
To identify appropriate candidates for rescue PCI, rapid,
simple and readily available bedside measures of the success
or failure of epicardial reperfusion are needed. ST resolution
has been extensively evaluated for this purpose (7–11). Early
studies were limited by small size, the use of different
measurement techniques and definitions for ST resolution,
varying time points for ECG and angiographic measure-
ments and the retrospective definition of thresholds for ST
resolution. Despite these important methodologic differ-
ences, the aforementioned studies yielded remarkably sim-
ilar results, suggesting that ST resolution is a highly accurate
predictor of infarct artery patency (positive predictive value
90%) but inaccurate for predicting IRA occlusion (nega-
tive predictive value approximately 50%) (10,11,34–36).
In the largest studies comparing angiographic measures
of reperfusion with simultaneous measurements of ST
resolution, a significant stepwise correlation has been ob-
served between greater ST resolution and higher rates of
IRA patency and TIMI grade 3 flow (37,38) (Fig. 3). After
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Figure 1. Examples of the correspondence between the sum of ST segment
elevations (ST) from epicardial leads and the ST from precordial leads
at 5-min intervals after experimental coronary artery occlusion. (A)
Correlation between epicardial ST and precordial ST when the occlu-
sion was maintained. (B) correlation between epicardial ST and precor-
dial ST when one of the two occlusions was released at 15 min (arrow).
Note the marked fall in both epicardial and precordial ST after reperfu-
sion of the larger of the two vessels. Adapted from Muller JE, Maroko PR,
Braunwald E. Evaluation of precordial electrocardiographic mapping as a
means of assessing changes in myocardial ischemic injury. Circulation
1975;52:16–27.
Figure 2. ST segment resolution 180 min after administration of therapy
and mortality (at time points between 21 to 35 days) in four trials of
thrombolytic therapy in acute myocardial infarction. All studies found
statistically significant mortality differences between the three groups of ST
resolution. GUSTO-III  Global Use of Strategies to Open Occluded
Coronary Arteries study; HIT-4  Hirudin for Improvement of Throm-
bolysis (HIT)-4 study; INJECT  International Joint Efficacy Compari-
son of Thrombolytics study; ISAM  Intravenous Streptokinase in Acute
Myocardial Infarction. Data abstracted from references 12, 13 and 40. The
GUSTO-III data are abstracted from Anderson R, White H, Ohmann E,
et al. Resolution of ST segment elevation 90 minutes after thrombolysis for
acute myocardial infarction predicts outcome: a GUSTO III substudy
(abstr). J Am Coll Cardiol 1998;31 Suppl A:371A.
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tissue plasminogen activator (tPA), 35% to 40% of patients
achieve complete (70%) ST resolution 90 min after
therapy, as defined using Schro¨der’s criteria (20,39); in
contrast, after streptokinase, only approximately 25% of
patients achieve complete ST resolution at 90 min (40). By
180 min, differences between the two agents are no longer
apparent, as tPA and streptokinase each achieve complete
ST resolution in approximately 50% of patients (39,40).
Despite differences between tPA and streptokinase in the
proportion of patients who achieve complete ST resolution
90 min after therapy, the correlation between ST resolution
and epicardial blood flow at 90 min is similar for the two
drugs (Fig. 3). Patients with complete ST resolution at
90 min have a 92% to 94% likelihood of IRA patency and
a 70% to 80% probability of TIMI grade 3 flow (37,38).
However, the absence of ST resolution does not accurately
predict an occluded IRA in that approximately 50% of
patients with no (30%) ST resolution still have a patent
IRA (37,38). Previously, the absence of ST resolution
despite a patent IRA had been considered to be a false
positive of the 12-lead ECG. As will be discussed in the
following text, in such patients, the ECG, rather than the
angiogram, may better reflect the adequacy of myocardial
reperfusion.
Impact of infarct location on the relationship between
ST resolution and TIMI flow grade. Important differ-
ences exist between anterior and inferior MI with regard to
ST segment resolution (8,9,12,13,38,41,42). Patients with
anterior infarction develop significantly less ST resolution
than those with inferior infarction, despite only modest
differences in epicardial blood flow, suggesting that ST
resolution is a less accurate predictor of epicardial reperfu-
sion among patients with anterior versus inferior MI
(8,12,13,38,41). This may be due to technical factors, such
as the frequent (normal) presence of J point elevation in the
anterior precordial leads (43), which would serve to decrease
the extent of ST segment resolution that is possible.
Additionally, anterior MI typically is associated with a
larger infarct size and greater tissue injury than inferior MI.
As a result, different threshold levels of ST resolution may
be appropriate for anterior versus inferior MI (38,41).
When sensitivity analyses are performed, it appears that
resolution of ST deviation by 70% is the optimal thresh-
old for patients with inferior MI, whereas resolution by
50% may be optimal for anterior MI (38). As will be
discussed in the following text, however, these threshold
effects are probably relevant only with regard to the predic-
tion of IRA patency. In terms of prognosis, a greater degree
of ST resolution is associated with lower mortality for both
anterior and inferior infarction (12,13).
Differentiating TIMI flow grade 2 from TIMI flow grade
3. Patients with TIMI grade 3 flow demonstrate signifi-
cantly greater ST resolution than patients with TIMI grade
2 flow (36–38,44) (Fig. 4). Yet, among patients with
complete (70%) ST resolution, the probability of TIMI
grade 3 flow is only 70% to 80% (vs. an approximately 95%
probability of TIMI grade 2  3 flow). Thus, while
“complete” ST resolution confirms that the infarct artery is
patent, it does not confirm that TIMI grade 3 flow is
present with 80% accuracy (36,37) (Fig. 3). However,
mortality appears to be similar between patients with TIMI
grade 2 flow and TIMI grade 3 flow if they have similar
degrees of ST resolution (38).
Combination of ST resolution with other noninvasive
predictors of failed reperfusion. Given the limitations of
using ST resolution alone to identify patients with failed
epicardial reperfusion, efforts have been made to evaluate
other noninvasive predictors of IRA patency, including
chest pain resolution and rapid washout of serum cardiac
biomarkers (10,35,36,45,46). Although persistent chest
pain after fibrinolytic therapy does identify patients who are
significantly more likely to have an occluded infarct artery or
Figure 3. ST resolution versus Thrombolysis In Myocardial Infarction (TIMI) flow grade. The reperfusion regimens used in the TIMI-14 substudy were
tissue plasminogen activator (tPA) and combinations of abciximab plus reduced-dose tPA, whereas the fibrinolytic agent used in Hirudin for Improvement
of Thrombolysis study (HIT-4) was streptokinase. p 0.001 for the correlation between ST resolution and TIMI 3 flow; p 0.001 for correlation between
ST resolution and infarct-related artery patency (TIMI 2  3 flow). Adapted from references 37 and 38.
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TIMI grade 3 flow (9,45,47–49), this subjective measure
is not sufficiently accurate to guide clinical decision making
independent of other criteria (10,45,49). Of the cardiac
biomarkers studied to date, early release of myoglobin
appears to be superior to creatine kinase MB and the
cardiac-specific troponins for the assessment of reperfusion,
due to its cytosolic location, small size and rapid release and
washout (50–54). Assessment of the rate of increase in
serum myoglobin over the first 60 to 90 min after fibrino-
lysis, or the ratio of myoglobin at 60 or 90 min/baseline,
appears to allow early assessment of IRA patency (50–54).
The use of more specific, even smaller molecules for this
purpose, such as heart-type fatty acid binding protein, does
not appear to improve predictive accuracy versus myoglobin
(55). Prediction of the status of the IRA using cardiac
biomarkers suffers from the same limitations as ST segment
analysis, namely that the there are many “false positive”
diagnoses of failed fibrinolysis (46,49,50).
Several studies have integrated cardiac biomarker data
with ST resolution and other clinical data to improve the
predictive accuracy for noninvasive identification of candi-
dates for rescue PCI (35,56). We have recently shown that
ST resolution, chest pain resolution and the concentration
of serum myoglobin can be used together to predict failure
of epicardial reperfusion (49). We prospectively identified
three criteria for failed epicardial reperfusion: ST resolution
50% at 90 min, persistent chest pain at 90 min and a 60
min/baseline ratio of serum myoglobin 4. The 12% of
patients who satisfied all three criteria had a 76% probability
of failing to achieve TIMI grade 3 flow in the infarct artery
90 min after fibrinolysis and a 57% probability of having an
occluded infarct artery (Fig. 5); on the other hand, the
approximately 60% of patients who satisfied 0 or 1 of these
criteria had only a 6% or lower probability of IRA occlusion,
an approximately 20% probability of achieving  TIMI
grade 3 flow and a 30-day mortality of approximately 1%
(Fig. 5). Even when used in combination, these noninvasive
criteria remain limited by false positive diagnoses of failed
epicardial reperfusion; however, using these criteria in com-
bination clearly improves prediction versus the use of these
criteria individually. A potential algorithm for detecting
failed epicardial reperfusion is shown in Figure 6.
ST RESOLUTION AS A MARKER OF
MYOCARDIAL AND MICROVASCULAR REPERFUSION
The previous discussion addressed the practical question of
how best to identify patients with failure of epicardial
reperfusion. Even among those who achieve normal epicar-
dial flow, however, tissue-level perfusion may be inadequate.
Using myocardial contrast echocardiography, it has been
demonstrated that many patients with successful epicardial
Figure 4. Differences in ST resolution between patients with Thrombolysis
In Myocardial Infarction (TIMI) grade 2 and TIMI grade 3 epicardial
blood flow. Adapted from de Lemos JA, Antman EM, McCabe CH, et al.
ST segment resolution and infarct related artery patency and flow after
thrombolytic therapy. Am J Cardiol 2000;85:299–304.
Figure 5. Correlation between noninvasive predictors of failed epicardial
reperfusion and infarct artery patency, flow and mortality. The three
noninvasive criteria for failed reperfusion are: ST resolution 50% at
90 min, 60 min/baseline ratio of serum myoglobin 4 and persistent chest
pain at the time of coronary angiography. IRA  infarct-related artery;
TIMI  Thrombolysis In Myocardial Infarction. Reproduced with per-
mission from de Lemos JA, Morrow DA, Gibson CM, et al. Early
noninvasive detection of failed epicardial reperfusion after fibrinolytic
therapy. Am J Cardiol 2001;88:353–8.
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reperfusion have “no reflow” at the level of the coronary
microcirculation and myocardium (14). Patients with TIMI
grade 3 flow in the infarct artery, but no-reflow at the
tissue-level, have poor recovery of left ventricular function
after MI and are at high risk for the development of CHF
and death (14). Investigators have confirmed these obser-
vations using other measures of tissue perfusion, including
Doppler flow-wire measurements (19), nuclear scintigraphy
(57), cardiac magnetic resonance imaging (MRI) (58) and
positron emission tomography (PET) scanning (59). Re-
cently, novel angiographic measures of microvascular
“blush” have been developed that provide risk stratification
independent of TIMI flow grade (60,61).
Taken together, these studies challenge the concept that
TIMI grade 3 flow alone is indicative of successful reper-
fusion and suggest that markers of myocardial and micro-
vascular perfusion will provide additive and independent
prognostic value. Since none of the aforementioned imaging
tests is readily available to the clinician at the bedside, ST
resolution has re-emerged as a simple and universally
available means of assessing tissue-level reperfusion. Studies
using both contrast echocardiography and angiographic
“blush” scores have shown that, among patients with normal
epicardial blood flow, persistent ST elevation is usually
indicative of impaired tissue and microvascular perfusion
(60,62,63).
ST SEGMENT RESOLUTION AND PROGNOSIS
Early studies using ST segment resolution demonstrated
that patients with rapid ST resolution had smaller infarcts
than those with persistent ST elevation (8). Substudies from
several large trials have further evaluated the relationship
between ST resolution and clinical end points. The Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto Mio-
cardico (GISSI) investigators, in a study of 7,426 patients,
found that two-thirds of patients had 50% ST resolution
4 h after thrombolysis; these patients had a 30-day mortality
rate of 3.5% versus 7.4% in the patients with 50% ST
resolution (64). Schro¨der et al. (12,13,40) have used a
three-component definition for resolution of the sum of ST
elevation 180 min after fibrinolysis: complete (70%),
partial (30% to70%) and none (30%). In a series of large
fibrinolytic trials, these investigators have demonstrated a
strong, stepwise correlation between the degree of ST
resolution at 180 min and subsequent mortality (12,13,40)
(Fig. 2).
More recently, it has been shown that an assessment of
ST resolution even earlier than 3 to 4 h after the onset of
fibrinolytic therapy can be used for risk stratification; both
60- and 90-min determinations of ST resolution provide
excellent discrimination of the risk for death and CHF in
patients receiving tPA-based fibrinolytic regimens (65–68)
(Table 1). Furthermore, it appears that patients who de-
velop complete ST resolution by 60 min are at even lower
risk for death and heart failure than those who develop
complete ST resolution by 90 min (68). Because of the
slower onset of fibrinolytic activity with streptokinase,
90 min appears to be too early to make a definitive
statement on ST resolution with this agent; 180 min may be
a more appropriate time to assess the efficacy of reperfusion
with streptokinase (40).
In addition to its ability to predict mortality, the degree of
ST resolution also predicts the development of left ventric-
ular dysfunction and clinical CHF. More complete ST
resolution consistently has been associated with smaller
infarct size and improved left ventricular function
(8,42,69,70). Similar to mortality, the probability of CHF
decreases in a stepwise fashion with greater degrees of ST
segment resolution (12,13,42,67,68,71,72) (Table 1).
Of particular importance is the observation that the
prognostic power of ST resolution persists even after ac-
counting for the effects of epicardial blood flow. In the
Figure 6. Proposed algorithm for the noninvasive detection of failed epicardial reperfusion. Percentages shown are the expected proportion of patients with
an occluded infarct artery (Thrombolysis In Myocardial Infarction [TIMI] 0/1 flow). IRA  infarct-related artery; MYO  myoglobin; ST RES  ST
resolution.
1287JACC Vol. 38, No. 5, 2001 de Lemos et al.
November 1, 2001:1283–94 ST Segment Resolution After Reperfusion Therapy
TIMI 14 substudy described in the preceding text, among
patients with a patent infarct artery 90 min after thrombol-
ysis, those with 70% ST resolution had a tenfold increase
in mortality versus those with complete (70%) ST reso-
lution (38). Interestingly, when patients were characterized
as to whether they had complete (70%) or incomplete
(70%) ST resolution, there was no difference in mortality
between patients with TIMI grade 2 flow and TIMI grade
3 flow (38). Using continuous ST monitoring, the Hirulog
Early Reperfusion/Occlusion-1 investigators have shown
that patients with early, stable ST recovery have improved
infarct zone wall motion, independent of TIMI flow grade
(72). In a substudy from the Thrombolysis and Angioplasty
in Myocardial Infarction (TAMI)-7 and the Global Use of
Strategies to Open Occluded Coronary Arteries
(GUSTO)-1 trials, ST resolution, but not TIMI flow grade,
was an independent predictor of mortality and CHF (71).
Additional support for the independent prognostic value
of ST resolution comes from the experience with primary
PCI for STEMI. After successful primary PCI, in which
TIMI grade 3 flow is established in the infarct artery,
persistent ST elevation is associated with poor recovery of
left ventricular function and increased mortality (70,73–75).
Patients with an increase in ST elevation after PCI (ST
segment re-elevation) appear to be at even higher risk for
the development of death and heart failure due to extensive
infarction, distal embolization or reperfusion injury (74,76–
78).
Taken together, these studies support the hypothesis that
ST resolution is a surrogate for tissue-level reperfusion.
When “complete” ST resolution is seen 90 min after
fibrinolysis, successful reperfusion has occurred at both the
epicardial and microvascular level, and the prognosis is
excellent. Persistent ST elevation, on the other hand,
appears to be indicative of either an occluded IRA or a
patent artery with failure of myocardial and microvascular
reperfusion.
Integration with other prognostic markers in ST eleva-
tion MI. Baseline clinical variables such as age, body
weight, infarct location, time to treatment, evidence for
CHF or shock, and the presence of diabetes, hypertension
or prior coronary artery disease can be used to predict the
risk for death among patients presenting with STEMI (79).
In studies performed to date, greater ST resolution is
predictive of lower mortality in both high- and low-risk
subsets defined using clinical factors, and is also an inde-
pendent risk predictor in multivariate models (12,13,40,67).
Recently, it has been shown that additional prognostic
information can be obtained from the level of cardiac
biomarker elevation before the administration of fibrinolytic
therapy. Patients with an elevated myoglobin (67) or cardiac
troponin T (80–82) concentration before fibrinolysis are at
high risk for development of death and CHF due to
extensive myocardial necrosis that had developed before
therapy was initiated. A handheld myoglobin assay per-
formed at the bedside immediately before fibrinolysis and
ST resolution assessed 60 to 90 min after the onset of
therapy can be used in combination to predict risk in
patients with STEMI; these two markers provide prognos-
tic information that is independent of baseline clinical
markers of risk, and discriminate a 25-fold gradient of risk
within 90 min of fibrinolysis (67) (Fig. 7).
THE USE OF ST RESOLUTION TO
COMPARE DIFFERENT REPERFUSION REGIMENS
Due to its ease of use and universal availability, ST resolu-
tion has long been considered as a potentially useful means
of comparing different therapies for ST elevation MI. In a
retrospective analysis of data from the Intravenous Strep-
tokinase in Acute Myocardial Infarction trial, Schro¨der et
al. (12) found greater ST segment resolution among patients
Figure 7. Stratified analyses of 30-day mortality based on the status of a
bedside myoglobin assay performed immediately before fibrinolysis, and
ST resolution, measured 60 to 90 min after fibrinolysis. ST RES  ST
resolution. Adapted with permission from de Lemos JA, Antman EM,
Giugliano RP, et al. Very early risk stratification after thrombolytic therapy
with a bedside myoglobin assay and the 12-lead electrocardiogram. Am
Heart J 2000;140:373–8.
Table 1. Comparison of 60- and 90-min Measurements of
ST Resolution
Outcome
ST Resolution
p
Trend
Complete
(>70%)
Partial
(30% to <70%)
None
(<30%)
60 min ST resolution:
n 295 (33%) 268 (30%) 337 (37%)
Death, 30 days (%) 1.7 4.5 7.7 0.002
Death, 1 year (%) 2.7 7.5 10.7 0.0005
CHF, 30 days (%) 7.1 13.8 17.2 0.0007
90 min ST resolution:
n 318 (41%) 243 (32%) 203 (27%)
Death, 30 days (%) 3.1 5.3 8.9 0.02
Death, 1 year (%) 4.7 7.4 11.3 0.02
CHF, 30 days (%) 8.5 12.8 15.3 0.05
Adapted from de Lemos JA, Antman EM, Giugliano RP, et al. Comparison of a 60
versus 90-min determination of ST-segment resolution after thrombolytic therapy for
acute myocardial infarction. Am J Cardiol 2000;86:1235–7.
CHF  congestive heart failure.
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who received streptokinase than among those who received
placebo; in the overall trial, there was a similar trend in
mortality favoring streptokinase. Similar observations were
made in the International Joint Efficacy Comparison of
Thrombolytics (INJECT) trial, in which reteplase was
associated with greater ST resolution and a trend towards
lower mortality than streptokinase (13). Other small trials,
not powered for mortality, have incorporated ST segment
analysis into composite assessments of clinical efficacy
(16,83,84).
Several factors have increased interest in using ST reso-
lution as a surrogate efficacy measure in reperfusion trials.
First, measurement of epicardial flow using coronary an-
giography, the “gold standard” used to identify promising
reperfusion regimens for testing in large mortality trials, has
proven disappointing in its ability to distinguish different
reperfusion regimens and doses. For example, a phase II
trial (85) found a higher rate of TIMI grade 3 flow with
reteplase than with alteplase, but this agent was not associ-
ated with a lower mortality than alteplase in a large phase III
study (86). Second, as discussed above, ST resolution has
been shown to provide prognostic information independent
of epicardial blood flow because it also reflects tissue and
microvascular perfusion. As such, it may be a better surro-
gate marker than epicardial blood flow (71) and, at the very
least, appears to provide complementary information for
assessing therapeutic efficacy. Finally, certain therapies may
be particularly beneficial in the coronary microcirculation.
For example, Neumann et al. (19) demonstrated that,
among patients undergoing PCI for MI, Doppler peak flow
velocity (a measure of microvascular function) was improved
over 14 days in patients who received adjunctive therapy
with the platelet GP IIb/IIIa inhibitor abciximab. This
finding was accompanied by improved regional and global
left ventricular function.
ST resolution has been used to evaluate newer reperfusion
regimens that incorporate combinations of GP IIb/III
inhibitors and fibrinolytics (Fig. 8). In the Integrilin to
Minimize Platelet Aggregation and Coronary Thrombosis-
Acute Myocardial Infarction study (IMPACT-AMI), com-
bination therapy with eptifibatide and alteplase improved
the time to steady state ST recovery versus alteplase alone
(16) (Fig. 8). Similarly, in the Platelet Aggregation Recep-
tor Antagonist Dose Investigation and Reperfusion Gain in
Myocardial Infarction trial (PARADIGM), lamifiban im-
proved ST resolution when given in combination with
fibrinolytic therapy (83) (Fig. 8). The TIMI 14 trial
compared the combination of abciximab and reduced doses
of fibrinolytics with full-dose fibrinolytics alone. In the
primary outcome analysis of the study, the combination of
abciximab and reduced-dose alteplase (tPA) resulted in a
significant improvement in epicardial flow (increased TIMI
grade 3 flow rates and lower TIMI frame counts at 60 and
90 min) when compared with tPA alone (17). All 346
patients with interpretable baseline and 90 min ECGs
treated with either tPA alone or abciximab plus reduced-
dose tPA (combination therapy) were included in an ST
resolution substudy (20). Patients who received combina-
tion therapy had a higher probability of complete ST
resolution than those receiving tPA alone (59% vs. 37%;
p  0.0001) (Fig. 8). Even after controlling for differences
in epicardial blood flow, patients receiving combination
therapy had significantly greater ST resolution than those
receiving tPA alone (Fig. 8). This benefit appeared to be
present regardless of the fibrinolytic agent and dose used,
suggesting that this effect was due to abciximab rather than
Figure 8. Overview of studies using ST resolution (ST RES) to compare standard fibrinolytic therapy with reperfusion regimens containing glycoprotein
IIb/IIIa inhibitors and reduced doses of fibrinolytics (combination therapy). In the Integrilin to Minimize Platelet Aggregation and Coronary
Thrombosis-Acute Myocardial Infarction (IMPACT-AMI) and Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in
Myocardial Infarction (PARADIGM) studies, where continuous ST monitoring was performed, combination therapy was associated with more rapid ST
recovery than was standard fibrinolytic therapy. In the Thrombolysis In Myocardial Infarction (TIMI) 14 study, where static ST monitoring was performed,
combination therapy was associated with a greater likelihood of achieving complete (70%) ST resolution, even after limiting the analysis to patients with
normal (TIMI grade 3) epicardial blood flow. Pts  patients; TFG3  TIMI grade 3 flow. Adapted from references 16, 20 and 83.
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the fibrinolytic agent. It was concluded that combination
therapy with abciximab and reduced-dose fibrinolytic ther-
apy improved myocardial perfusion in addition to epicardial
flow (20). The promising findings with combination reper-
fusion therapy were confirmed in two companion studies,
which evaluated abciximab with reduced-dose reteplase
instead of alteplase (18,87). A large phase III trial,
GUSTO-V, recently reported 30-day safety and efficacy
outcomes for this reperfusion strategy. Patients randomized
to receive combination therapy with abciximab and
reduced-dose reteplase had a nonsignificant 0.3% reduction
in 30-day mortality versus patients randomized to reteplase
alone (88). The results of long-term follow-up in this study,
as well as the results of other ongoing trials evaluating
different combinations of GP IIb/IIIa inhibitors and fi-
brinolytics, are eagerly awaited.
In a related analysis from the TIMI 14 study, the degree
of ST segment resolution after early adjunctive PCI was
determined. Among patients who underwent adjunctive
PCI between 90 and 180 min after fibrinolysis, those who
had initially been treated with a combination regimen
containing abciximab had significantly greater ST resolution
after PCI and a lower likelihood of ST re-elevation than
patients who had been treated with a fibrinolytic alone (89).
Furthermore, the percutaneous procedure itself was associ-
ated with enhanced ST resolution among patients who had
received abciximab but not those who had received a
fibrinolytic alone (89) (Fig. 9). These findings suggest that
abciximab may prevent the microvascular injury that fre-
quently occurs when adjunctive PCI is performed early after
the administration of fibrinolytic therapy.
METHODOLOGIC CONSIDERATIONS
Single lead versus sum of ST segments. Investigators
have used a variety of different techniques for measuring ST
deviation including choosing the single lead with the great-
est baseline ST deviation, summing some or all leads with
ST elevation and summing both ST elevation and reciprocal
ST depression. Although few direct comparison studies are
available, single-lead techniques appear to provide compa-
rable results to multilead techniques for the prediction of
epicardial patency, provided the lead is left in an identical
position from tracing to tracing (90). However, single-lead
techniques may not be sufficient for prognostic assessment.
To date, the large prognostic trials (12,13,40,66,73) and the
studies comparing ST resolution with specific indexes of
microvascular perfusion (60,62,63) have utilized sums of ST
deviation from standard 12-lead ECGs. Comparative stud-
ies are needed in which single-lead and multiple-lead
measurements are prospectively defined and directly com-
pared.
Static versus continuous ST monitoring. This discussion
has focused primarily on the use of static ST segment
monitoring—the comparison of two ECGs 60 to 180 min
apart. However, the use of only two static ECGs has several
important limitations. First, the actual peak of ST deviation
may be missed, and, as a result, the degree of ST resolution
may be underestimated (90), contributing to the high “false
positive” rate for coronary occlusion that has been observed.
Second, coronary reperfusion is a dynamic process with
transient changes in epicardial flow patterns observed fre-
quently in the early hours after reperfusion (48). Reocclu-
sion also occurs frequently after initially successful fibrino-
lysis, is often asymptomatic and is associated with a
significant increase in the risk for adverse events (91,92).
Continuous ST segment monitoring can overcome some of
the limitations of static ST monitoring and improves the
likelihood of capturing the maximal point of ST deviation as
well as early episodes of reocclusion that are manifest by
recurrent ST elevation (9,90,93–95). ST segment re-
elevation that occurs 6 to 24 h after fibrinolysis appears to be
independently associated with worse outcomes (96). The
variable that appears to be most predictive using continuous
ST monitoring is the time to steady state ST recovery,
usually defined as 50% reduction of the ST elevation in
the single lead with greatest peak ST elevation, without
episodes of early ST re-elevation (34,48,90,95,97). Unfor-
tunately, continuous ST monitoring is not widely available,
requires additional personnel and training, and may be
difficult to perform rapidly in acutely ill patients. In addi-
tion, studies of continuous ST monitoring performed to
date have been designed to address the question of IRA
patency rather than prognosis.
We recommend that frequent static ST monitoring be
performed after fibrinolytic therapy in the majority of
Figure 9. Subset of patients from the Thrombolysis In Myocardial Infarc-
tion (TIMI) 14 trial with TIMI grade 3 flow in the infarct artery at 90 min.
Comparison of mean percent ST resolution from 90 to 180 min between
patients who did and did not undergo early adjunctive percutaneous
coronary intervention (PCI) between 90 to 180 min after fibrinolysis.
Patients are further separated into those who received and did not receive
abciximab (Abx) as part of the reperfusion regimen. In the presence of Abx
pretreatment, early adjunctive PCI was associated with greater ST resolu-
tion, whereas in the absence of Abx pretreatment, ST resolution tended to
be worse in patients who underwent PCI. Reproduced with permission
from de Lemos JA, Gibson CM, Antman EM, et al. Abciximab and early
adjunctive percutaneous coronary intervention are associated with im-
proved ST segment resolution after thrombolysis: observations from the
TIMI 14 trial. Am Heart J 2001;141:592–8.
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centers where high-quality continuous ST monitoring is not
currently available. Twelve-lead ECGs should be performed
immediately before fibrinolysis and then at 60 and 90 min
after fibrinolysis. After treatment with streptokinase, later
measurements (at 90 and 180 min) of ST resolution are
probably more appropriate. Electrocardiograms should be
obtained serially at least every 6 to 8 h through the first 24 h
to assess for silent reocclusion. Alternatively, continuous ST
monitoring may be particularly effective in the time period
from 3 to 24 h after fibrinolysis, when the goal of ST
monitoring shifts towards the detection of silent reocclu-
sion. Here, the technical challenge of rapidly placing a
continuous ST monitor is likely to be a less important
limitation than it is in the early phase of infarction, when
continuous ST monitoring may be too cumbersome for
widespread clinical use.
FUTURE DIRECTIONS
The resurgent interest in using ST resolution as a bedside
marker of reperfusion has stimulated additional research in
this area. The results from the TIMI 14, PARADIGM and
IMPACT-AMI trials, taken together with the large out-
come trials from Schro¨der and others, suggest that ST
resolution may be a suitable surrogate marker for phase II
trials testing novel reperfusion regimens. Replacing angiog-
raphy with ST resolution may allow these trials to be
performed at lower expense and perhaps with more preci-
sion. The Fibrinolytics and Aggrastat with ST Elevation
Resolution trial is a phase II study comparing tenecteplase
with the combination of tirofiban and reduced-dose tenect-
eplase. The dose-confirmation phase of this study will
utilize an ST resolution measurement as the primary end
point.
Several important caveats require mention with regard to
trial design. As noted above, ST segment resolution differs
between anterior and inferior infarction (38), and studies
that do not account for these differences may yield invalid
results. Of note, Gibson et al. (98) reported that epicardial
blood flow is also slower with infarcts in the region of
distribution of the left anterior descending artery than
infarcts in the other arterial beds (98). Due to these
differences, we recommend that, in phase II trials compar-
ing novel thrombolytic regimens, a stratified randomization
scheme be used for subjects with anterior versus nonanterior
infarction.
Additional work is needed to clarify the relationship
between ST segment resolution and other indexes of mi-
crocirculatory function, including contrast echocardiogra-
phy, MRI, nuclear scintigraphy, PET scanning and Dopp-
ler flow-wire techniques. Future trials that evaluate these
imaging modalities should incorporate measures of ST
segment resolution to help clarify the relationship between
simple bedside measures and the more complex and expen-
sive imaging modalities. Additionally, ST resolution may be
particularly useful in the study of novel adjunctive therapies,
such as those designed to provide myocardial protection and
prevent reperfusion injury. Finally, on a more practical level,
more research is needed in which ST resolution is combined
with other noninvasive measures of reperfusion to help
clinicians make real-time decisions about which patients
should be taken emergently for “rescue” PCI.
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